Dieser Anti-PDCL3 Antikörper ist ein Kaninchen Polyklonal Antikörper zur Detektion von PDCL3 in WB, ELISA, IF und IHC (p). Geeignet für Human, Maus und Ratte.
Produktnummer ABIN6992031
Kurzübersicht für PDCL3 Antikörper (C-Term) (ABIN6992031)
PDCL3 antibody is human, mouse and rat reactive. PDCL3 antibody is predicted to not cross-react with other members of the PDCL protein family.
Aufreinigung
PDCL3 antibody is affinity chromatography purified via peptide column.
Immunogen
PDCL3 antibody was raised against a 14 amino acid peptide near the carboxy terminus of human PDCL3. The immunogen is located within the last 50 amino acids of PDCL3.
PDCL3
Reaktivität: Human
WB, ELISA
Wirt: Maus
Monoclonal
AT8F9
unconjugated
Applikationshinweise
PDCL3 antibody can be used for detection of PDCL by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for Immunohistochemistry at 5 μ,g/mL. For Immunoflorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
PDCL3 antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
PDCL3 antibody can be stored at 4°C for three months and -20°C, stable for up to one year.
Target
PDCL3
(Phosducin-Like 3 (PDCL3))
Andere Bezeichnung
PDCL3
Hintergrund
Phosducin-like proteins (PhLPs) are a conserved family of proteins with thioredoxin-like domains that were initially identified as modulators of G protein signaling (1,2). PDCL3 is highly homologous to PDCL and shares an N-terminal helix domain and a C-terminal thioredoxin-fold (Trx-fold) domain (3). Along with the related protein PDCL2, PDCL3 interacts with the chaperonin CCT and modulates CCT-mediated actin and tubulin folding (4). Modulation of PDCL3 levels by MAPK phosphorylation and RhoA-dependent changes also promote cytoskeletal remodeling (5).